Daniel

Tiesse: “La nuova frontiera di crescita sono le tlc satellitari”

by

Vincenzo Luciano Lucrezia, chief operating officer della società italiana specializzata in router e apparati di rete: “Grazie all’alleanza con Cysec offriamo valore aggiunto”. Il numero uno della cybercompany elvetica Patrick Trinkler: “Puntiamo allo sviluppo dello space internet che connetterà miliardi di persone” Antonello Salerno “Il comparto delle telecomunicazioni satellitari potrebbe essere una grande occasione, per l’Italia e … Read more

Distalmotion Celebrates Milestone: Over 1000 Procedures Successfully Completed with the Surgical Robot Dexter®

by

May 15 , 2024 Distalmotion, a pioneer in surgical robotics, proudly announces the achievement of a significant milestone: surpassing 1000 successful procedures with its surgical robot, Dexter. Since its first commercial installation in 2022, Dexter has become a cornerstone in surgical innovation, treating patients everyday across multiple countries and institutions. This milestone underscores the maturity … Read more

STALICLA publishes on identification of first autism subgroup and matching treatment

by

May 8, 2024 Geneva, Switzerland, May 8, 2024 – STALICLA SA, a Swiss neuro precision biotech company, has provided proof-of-concept clinical data for DEPI (Databased Endophenotyping Patient Identification), its neuro precision discovery platform, enabling the identification of biological subgroups of patients with Autism Spectrum Disorder (ASD) and matching treatments, in a study published last week in … Read more

STALICLA initiates U.S. Phase 3 enabling DDI study of STP7 (Mavoglurant)

by

STALICLA initiates U.S. Phase 3 enabling DDI study of STP7 (Mavoglurant) to treat cocaine use disorder May 2, 2024 Geneva, Switzerland, May 2, 2024 – STALICLA SA, a late-stage biotechnology company specializing in precision medicine for brain disorders, announces the First Patient First Visit (FPFV) for the company’s drug-drug interaction (DDI) study of STP7 (Mavoglurant), an … Read more

Loi spatiale de l’UE : un fonctionnaire de la Commission européenne dévoile les aspects cyber de la législation

by

Type de contenu: Actualités Concernant la durabilité, le « niveau d’ambition [de la loi] sera assez faible », a averti M. de la Brosse, ajoutant qu’il n’existe actuellement aucune méthodologie pour calculer des effets de l’activité spatiale sur l’environnement. [Gorodenkoff / Shutterstock]  Euractiv fait partie de The Trust Project >>> Langues : English | Deutsch Imprimer     Un représentant de la Commission … Read more

Appointment will propel STALICLA’s mission to develop their late-stage clinical assets for precision brain disease treatment.

by

STALICLA Appoints Dr. Thomas Blaettler, MD Date: Friday, Jan. 19, 2024 GENEVA–(BUSINESS WIRE)– STALICLA SA, a Swiss clinical-stage biotechnology company focused on advancing precision medicine for brain diseases, announced today the appointment of Thomas Blaettler, to the position of Chief Medical Officer. Dr. Thomas Blaettler brings a wealth of pharmaceutical development experience and deep insights … Read more

« Au sein de l’Union européenne, il n’existe pour l’instant aucun cadre juridique harmonisé relatif aux activités spatiales »

by

Mathieu Bailly, vice-président de Cysec, plaide, dans une tribune au « Monde », en faveur d’une réglementation européenne obligatoire en matière de sécurité spatiale pour faire face aux risques sécuritaires, géopolitiques et économiques. Vous pouvez partager un article en cliquant sur les icônes de partage en haut à droite de celui-ci.La reproduction totale ou partielle d’un article, … Read more

HAYA Therapeutics Announces Collaboration with Lilly to Discover Novel Regulatory Genome Targets for Obesity and Related Metabolic Conditions Using Proprietary RNA Platform

by

LAUSANNE, Switzerland and SAN DIEGO, USA – Sept. 4, 2024 – HAYA Therapeutics, SA, a biotechnology company pioneering precision RNA-guided regulatory genome targeting therapeutics for chronic diseases, today announced a multi-year agreement with Eli Lilly and Company to apply HAYA’s advanced RNA-guided regulatory genome platform to support preclinical drug discovery efforts in obesity and related metabolic conditions. … Read more

Stalicla’s series B adds $17.4M for trials in substance abuse disorders, ASD

by

Stalicla SA Secures $17.4 Million in Series B Funding to Advance Innovative Therapies Subtitle: Funding Enables Progress in Treating Cocaine Misuse Disorder and Autism Spectrum Disorder Date: Friday, Jan. 19, 2024 Source: BioWorld (©2024 BioWorld. Reprinted with permission from Clarivate.) Stalicla SA Achieves First Close of $17.4 Million Series B Round for Therapeutic Development BioWorld, … Read more

Building on Existing Technologies

by

Building on Existing Technologies for a Commercial Prototype Within a Decade Transmutex is pioneering an entirely new type of nuclear energy that promises scalable carbon-free energy without the traditional challenges of existing nuclear plants. Today’s issues with nuclear energy are safety, long-lived waste, and proliferation. Transmutex will allow significant improvements on all these matters, while … Read more

daniel bertholet

4seeventures 

Chemin Falletti 6 C

1224 Chêne-Bougeries

Copyright © 2024

terms of service PRIVACY POLICY